Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+1.04%
SPX
+0.32%
IXIC
+0.14%
FTSE
0.00%
N225
-1.45%
AXJO
+0.53%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
8.03B
Dividend Yield
0.00%
P/E Ratio
14.40
EPS
3.50
Revenue
1.02B
Avg. Volume
2.11M

About

What does HALO do?
Halozyme Therapeutics, a San Diego-based biopharmaceutical company, specializes in drug delivery technology and has two proprietary products, Hylenex and XYOSTED, focusing on subcutaneous administration. Founded in 2003, it employs 373 people and partners with other firms for drug-device combinations.
Sector
💻 Health Care
IPO
CEO
Employees
350
Headquarters
California, USA
Website
http://www.halozyme.com

Recently from Cashu

publisher logo
Cashu

Halozyme Therapeutics Sees Decreased Short Interest, Indicating Positive Investor Sentiment Shift

4 days ago
publisher logo
Cashu

Halozyme Therapeutics: Innovating Drug Delivery Solutions for Enhanced Biopharmaceutical Therapies

21 days ago
publisher logo
Cashu

Halozyme Therapeutics: HALO AirFinance Fuels Aviation Growth with Tailored Financing for Royal Jordanian

27 days ago
Stocks
Health Care
halo
Halozyme Therapeutics
NASDAQ: HALO
+1.10 (+1.72%)
65.14
USD
At close at Aug 13, 20:37 UTC
Summary
News
Signals
Benchmarks
Financials